Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,800 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 12,300 · Balance 14,100 Row 2 · 2026-08-10 · Sale · Disposed 12,300 · Balance 1,800 F1: This transaction was executed in multiple trades at prices ranging from $11.23 to $11.31. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2033-05-02 | Direct | 46,500 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 12,300 · Balance 46,500 F2: The shares underlying this option, which was granted on May 3, 2023, were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $11.23 to $11.31. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The shares underlying this option, which was granted on May 3, 2023, were fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionStock Option (right to buy) · Derivative | 12,300 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001434647-26-000070 · wk-form4_1786565760.xml · derivative · entry 3 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 12,300 shares Expires 2033-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option, which was granted on May 3, 2023, were fully vested. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 12,300 | $11.25 | $138,377.46 |
DisclosureSEC source: 0001434647-26-000070 · wk-form4_1786565760.xml · nonDerivative · entry 2 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.23 to $11.31. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 12,300 | $4.97 | $61,131.00 |
DisclosureSEC source: 0001434647-26-000070 · wk-form4_1786565760.xml · nonDerivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 18, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001434647-26-000053 · wk-form4_1781813758.xml · derivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 29, 2025 Filed May 31, 2025 01:38 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-019046 · rdgdoc.xml · derivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 00:05 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 300 | $7.84 | $2,351.52 |
DisclosureSEC source: 0001437749-25-010332 · rdgdoc.xml · nonDerivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Read SEC document |
| October 11, 2024 Filed Oct 16, 2024 20:46 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 500 | $7.92 | $3,957.65 |
DisclosureSEC source: 0001437749-24-031367 · rdgdoc.xml · nonDerivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| May 13, 2024 Filed May 16, 2024 01:15 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001437749-24-017180 · rdgdoc.xml · derivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2034-05-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 275 | $5.95 | $1,635.67 |
DisclosureSEC source: 0001437749-23-018447 · rdgdoc.xml · nonDerivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 00:35 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 325 | $5.52 | $1,794.00 |
DisclosureSEC source: 0001437749-23-017335 · rdgdoc.xml · nonDerivative · entry 2 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725 Read SEC document |
| May 30, 2023 Filed May 31, 2023 15:34 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 400 | $5.11 | $2,042.12 |
DisclosureSEC source: 0001437749-23-016221 · rdgdoc.xml · nonDerivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Read SEC document |
| May 03, 2023 Filed May 9, 2023 01:55 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 58,800 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001437749-23-013127 · rdgdoc.xml · derivative · entry 1 Watton Corey Michael · CIK 0001975404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,800 Underlying: Common Stock · 58,800 shares Expires 2033-05-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: 33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.